• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/1/25 5:00:33 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLTO alert in real time by email
    false 0001907223 0001907223 2025-03-26 2025-03-26 0001907223 us-gaap:CommonStockMember 2025-03-26 2025-03-26 0001907223 KLTO:WarrantsMember 2025-03-26 2025-03-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 26, 2025

     

    Klotho Neurosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-41340   86-2727441
    (Commission File Number)  

    (IRS Employer

    Identification No.)

     

    13576 Walnut Street, Suite A
    Omaha, NE 68144

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code (833) 931-6330

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Common Stock   KLTO   The Nasdaq Stock Market LLC
    Warrants   KLTOW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 1.01.Entry Into or Amendment of a Material Definitive Agreement.

     

    On March 26, 2025, Klotho Neurosciences, Inc. (the “Company”) entered into a Share Exchange Agreement (the “SEA”) with SkyBell Technologies, Inc., a Nevada corporation (“Seller”), and SB Security Holdings, LLC, a Delaware limited liability company (“SBSH”) and wholly-owned subsidiary of Seller, which is an internet connected video doorbell service company.  Pursuant to the SEA, the Company agreed to purchase all of the issued and outstanding membership interests in SBSH (the “Acquisition”) in exchange for a number of newly issued shares of the Company’s common stock equal to ninety percent (90%) of the total number of issued and outstanding shares of the Company’s common stock, on a fully-diluted basis, as of the closing of the Acquisition. The closing of the Acquisition is subject to customary closing conditions, including, but not limited to, mutual agreement as to the legal transaction structure, approval by the Company’s stockholders, Nasdaq approval, required third party approvals, including the approval of secured creditors, satisfactory due diligence reviews by both parties, the effectiveness of a Form S-4 Registration Statement with regard to the Acquisition and the closing occurring on or before August 13, 2025.

     

    The foregoing description of the SEA does not purport to be complete and is qualified in its entirety by reference to the SEA, a copy of each of which is filed herewith as Exhibit 2.1 and incorporated herein by reference.

     

    Item 9.01Financial Statements and Exhibits.

     

    Exhibits   Description
         
    2.1*   Share Exchange Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *Certain annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: April 1, 2025 KLOTHO NEUROSCIENCES, INC.
         
      By: /s/ Joseph Sinkule
      Name:  Joseph Sinkule
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $KLTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KLTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KLTO
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Klotho Neurosciences Inc.

      DEF 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)

      5/5/25 4:54:15 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klotho Neurosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

      4/21/25 5:15:08 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klotho Neurosciences Inc. filed SEC Form 8-K: Other Events

      8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

      4/4/25 5:15:08 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

      NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. The event will be held at the Hilton Hotel in Union Square, San Francisco during the J.P. Morgan Healthcare Week, and KLTO's Founder, CEO and Chairman, Dr. Joseph Sinkule, will give a presentation at 3:00 p.m. PT on Tuesday, January 14. Biotech Showcase 2025 Presentation Details:Date: Tuesday, Ja

      1/8/25 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board

      NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

      12/9/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Former Merck USA President Joins Klotho Neurosciences' Board of Directors

      NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser

      12/3/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board

      NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

      12/9/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Former Merck USA President Joins Klotho Neurosciences' Board of Directors

      NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser

      12/3/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

      NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

      10/23/24 6:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care